CytoDyn Announces Clinically Significant Top-line Results from its Phase 2 Trial in Mild-to-Moderate COVID-19 Patients Aug 11, 2020 9:15am EDT
CytoDyn Receives Positive DSMC Recommendation for Leronlimab Phase 3 COVID-19 Trial with No Safety Concerns Aug 04, 2020 4:12pm EDT
CytoDyn Completes Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share without Warrants Jul 29, 2020 6:56pm EDT
CytoDyn to Hold Conference Call on July 30 to Provide Updates on its Two COVID-19 Trials Jul 27, 2020 6:00am EDT
CytoDyn’s CEO Dr. Pourhassan to Appear on DrBeen Webcast Tomorrow July 18, 2020 Jul 17, 2020 5:31pm EDT
Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency’s suggestion Jul 13, 2020 6:00am EDT
